Clinical trial results:
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19

Summary

EudraCT number	2020-001803-17
Trial protocol	GB IT
Global end of trial date	10 February 2023

Results information

Result version number	v1
This version publication date	14 December 2023
First version publication date	14 December 2023

Trial information

Trial identification

Sponsor protocol code	GS-US-540-5823

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04431453
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., +44 1223 897284, clinical.trials@gilead.com
Scientific contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., +44 1223 897284, clinical.trials@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-002826-PIP01-20
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 February 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	10 February 2023
Global end of trial reached?	Yes
Global end of trial date	10 February 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of this study were to evaluate the safety, tolerability and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years.

The goals of this clinical study were to learn more about the study drug, RDV, and how safe it was in participants younger than 18 years with coronavirus disease 2019 (COVID-19) and who were hospitalized.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 July 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	United States: 44
Worldwide total number of subjects	59
EEA total number of subjects	14

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	1

wk	
Newborns (0-27 days)	5
Infants and toddlers (28 days-23 months)	13
Children (2-11 years)	24
Adolescents (12-17 years)	16
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in Italy, Spain, the United Kingdom, and the United States.

Pre-assignment

Screening details:

60 participants were screened. 59 participants were enrolled in this study and 58 were treated.

Pre-assignment period milestones

Number of subjects started	59
Number of subjects completed	58

Pre-assignment subject non-completion reasons

Reason: Number of subjects	Enrolled but Never Treated: 1

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg

Arm description:

Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to <40kg

Arm description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to <20kg

Arm description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg

Arm description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg

Arm description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 6:Age≥0-<14 Days, Gest. Age>37 Weeks;Weight≥2.5kg

Arm description:

Participants received RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV,Cohort 7:Age≥0-<56 Days, Gest. Age≤37 Weeks;Weight≥1.5kg

Arm description:

Participants received RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Arm title	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg

Arm description:

Participants received RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.

Arm type	Experimental
Investigational medicinal product name	Remdesivir
Investigational medicinal product code	GS-5734
Other name	Veklury®
Pharmaceutical forms	Injection
Routes of administration	Infusion

Dosage and administration details:

Administered via intravenous infusion.

Number of subjects in period 1[1]	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to <40kg	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to <20kg
Started	12	12	12
Completed	11	11	11
Not completed	1	1	1
Death	1	-	-
Withdrew consent	-	1	-
Lost to follow-up	-	-	1

Number of subjects in period 1[1]	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg	RDV,Cohort 6:Age≥0-<14 Days, Gest. Age>37 Weeks;Weight≥2.5kg
Started	12	3	1
Completed	9	3	1
Not completed	3	0	0
Death	-	-	-
Withdrew consent	2	-	-
Lost to follow-up	1	-	-

Number of subjects in period 1[1]	RDV,Cohort 7:Age≥0-<56 Days, Gest. Age≤37 Weeks;Weight≥1.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Started	1	5

Completed	1	4
Not completed	0	1
Death	-	1
Withdrew consent	-	-
Lost to follow-up	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One person from the worldwide number enrolled in the trial in Cohort 5 did not receive the treatment, hence, the number of subjects in the baseline period are not the same as the worldwide number enrolled.

Baseline characteristics

Reporting groups

Reporting group title	Overall Study

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	58	58	
Age categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Newborns (0-27 days)	5	5	
Infants and toddlers (28 days-23 months)	12	12	
Children (2-11 years)	24	24	
Adolescents (12-17 years)	16	16	
Preterm newborn - gestational age < 37 wk	1	1	
Gender categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Female	33	33	
Male	25	25	
Race			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
White	37	37	
Black or African American	15	15	
Other or More Than One Race	6	6	
Ethnicity			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Not Hispanic or Latino	34	34	
Hispanic or Latino	23	23	
Unknown or Not Reported	1	1	
Number of Participants With Clinical Status (7-Point Ordinal Scale) Score			
7-point scale: 1.Death;2.Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation(ECMO);3.Hospitalized, on noninvasive ventilation or high-flow oxygen devices;4.Hospitalized,requiring low-flow supplemental oxygen;5.Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care(COVID-19 related/otherwise);6.Hospitalized, not requiring supplemental oxygen-no longer requiring ongoing medical care(other than per-protocol RDV administration);7.Not hospitalized. Cohorts 6,7 are not reported due to participants' confidentiality			
Units: Subjects			
Score 1	0	0	
Score 2	15	15	
Score 3	20	20	
Score 4	10	10	

Score 5	12	12	
Score 6	1	1	
Score 7	0	0	
Oxygen Support Status			
Oxygen support status was derived from the 7-point ordinal scale, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Participants with Baseline oxygen status for scores: 2 'invasive mechanical ventilation'; 3 'High Flow Oxygen'; 4 'Low Flow Oxygen', and 5 or 6 'Room Air' are reported. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
High-flow oxygen	20	20	
Low-flow oxygen	10	10	
Room air	13	13	
Invasive mechanical ventilation	15	15	
Pediatric Early Warning Score (PEWS) Scale Score: Behavior			
Behavior:0=playing; appropriate; 1=sleeping; 2=irritable; 3=lethargic; confused; reduced response to pain. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Behavior: Score 0	22	22	
Behavior: Score 1	13	13	
Behavior: Score 2	8	8	
Behavior: Score 3	15	15	
PEWS: Cardiovascular Score			
Cardiovascular:0=normal; pink; capillary refill (cr) 1-2 seconds(secs);1=Tachycardia< 20 above normal for age;2=Tachycardia 20-29 above normal for age; gray; cr=4 secs;3=Tachycardia >=30 above/bradycardia >=10 below normal for age; Gray; cr>=5 secs. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Cardiovascular: Score 0	35	35	
Cardiovascular: Score 1	12	12	
Cardiovascular: Score 2	5	5	
Cardiovascular: Score 3	6	6	
PEWS: Respiratory Score			
Respiratory:0=Normal;1=Respiratory rate(rr)>10 above normal using accessory muscles; 30+%fraction of inspired oxygen(FiO2)/3+L/min; 2= rr>20 above normal and retractions;40%FiO2 or 6+L/min; 3 =rr>=5 below normal with retractions and grunting; 50%FiO2/8+L/min. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Respiratory: Score 0	17	17	
Respiratory: Score 1	10	10	
Respiratory: Score 2	12	12	
Respiratory: Score 3	19	19	
SARS-CoV-2 RNA Viral Load: Nasal/Oropharyngeal (OP) Swabs			
The assessment was done for the sample of nasal/OP swab. n= 5, 5, 4, 3, 1, 1; total = 19. Here, 'n' = participants with data available for the specific category. '9999' = Not available, data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	4.80		
standard deviation	± 1.998	-	
SARS-CoV-2 RNA Viral Load:			

Nasopharyngeal (NP)/ OP Swabs			
The assessment was done for the sample of NP/OP swab. n= 5, 4, 5, 7, 2, 4; total = 27. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL arithmetic mean standard deviation	 5.78 ± 1.802	 -	
SARS-CoV-2 RNA Viral Load: Endotracheal Tube Aspirates			
The assessment was done for the sample of endotracheal tube aspirates. n= 1, 4, 2, 3, 1, 0; total = 11. Here, 'n' = participants with data available for the specific category. '9999' = Not Available; data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL arithmetic mean standard deviation	 5.87 ± 2.180	 -	
SARS-CoV-2 RNA Viral Load: Rectal/Fecal Swabs			
The assessment was done for the sample of rectal/fecal swabs. n= 8, 7, 8, 11, 3, 5; total = 42. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL arithmetic mean standard deviation	 3.26 ± 1.297	 -	

Subject analysis sets

Subject analysis set title	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to<40kg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kgto<20kg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days	
Subject analysis set title	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.	

Subject analysis set title	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.

Reporting group values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to<40kg	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kgto<20kg
Number of subjects	12	12	12
Age categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	1
Children (2-11 years)	0	8	11
Adolescents (12-17 years)	12	4	0
Preterm newborn - gestational age < 37 wk			
Gender categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Female	8	7	5
Male	4	5	7
Race			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
White	7	9	6
Black or African American	5	2	4
Other or More Than One Race	0	1	2
Ethnicity			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Not Hispanic or Latino	8	5	5
Hispanic or Latino	3	7	7
Unknown or Not Reported	1	0	0
Number of Participants With Clinical Status (7-Point Ordinal Scale) Score			
7-point scale: 1.Death;2.Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation(ECMO);3.Hospitalized, on noninvasive ventilation or high-flow oxygen devices;4.Hospitalized,requiring low-flow supplemental oxygen;5.Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care(COVID-19 related/otherwise);6.Hospitalized, not requiring supplemental oxygen-no longer requiring ongoing medical care(other than per-protocol RDV administration);7.Not hospitalized. Cohorts 6,7 are not reported due to participants' confidentiality			
Units: Subjects			
Score 1	0	0	0
Score 2	1	3	3
Score 3	6	4	3
Score 4	2	3	0
Score 5	3	2	6
Score 6	0	0	0

Score 7	0	0	0
Oxygen Support Status			
Oxygen support status was derived from the 7-point ordinal scale, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Participants with Baseline oxygen status for scores: 2 'invasive mechanical ventilation'; 3 'High Flow Oxygen'; 4 'Low Flow Oxygen', and 5 or 6 'Room Air' are reported. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
High-flow oxygen	6	4	3
Low-flow oxygen	2	3	0
Room air	3	2	6
Invasive mechanical ventilation	1	3	3
Pediatric Early Warning Score (PEWS) Scale Score: Behavior			
Behavior:0=playing; appropriate; 1=sleeping; 2=irritable; 3=lethargic; confused; reduced response to pain. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Behavior: Score 0	7	6	5
Behavior: Score 1	3	3	2
Behavior: Score 2	1	0	2
Behavior: Score 3	1	3	3
PEWS: Cardiovascular Score			
Cardiovascular:0=normal; pink; capillary refill (cr) 1-2 seconds(secs);1=Tachycardia< 20 above normal for age;2=Tachycardia 20-29 above normal for age; gray; cr=4 secs;3=Tachycardia >=30 above/bradycardia >=10 below normal for age; Gray; cr>=5 secs. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Cardiovascular: Score 0	9	7	7
Cardiovascular: Score 1	1	2	3
Cardiovascular: Score 2	2	1	0
Cardiovascular: Score 3	0	2	2
PEWS: Respiratory Score			
Respiratory:0=Normal;1=Respiratory rate(rr)>10 above normal using accessory muscles; 30+%fraction of inspired oxygen(FiO2)/3+L/min; 2= rr>20 above normal and retractions;40%FiO2 or 6+L/min; 3 =rr>=5 below normal with retractions and grunting; 50%FiO2/8+L/min. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Respiratory: Score 0	4	1	6
Respiratory: Score 1	2	5	2
Respiratory: Score 2	3	2	2
Respiratory: Score 3	3	4	2
SARS-CoV-2 RNA Viral Load: Nasal/Oropharyngeal (OP) Swabs			
The assessment was done for the sample of nasal/OP swab. n= 5, 5, 4, 3, 1, 1; total = 19. Here, 'n' = participants with data available for the specific category. '9999' = Not available, data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	5.35	4.87	3.18
standard deviation	± 1.796	± 2.807	± 0.967
SARS-CoV-2 RNA Viral Load: Nasopharyngeal (NP)/ OP Swabs			
The assessment was done for the sample of NP/OP swab. n= 5, 4, 5, 7, 2, 4; total = 27. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due			

to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	5.93	5.37	5.67
standard deviation	± 2.172	± 1.879	± 2.273
SARS-CoV-2 RNA Viral Load: Endotracheal Tube Aspirates			
The assessment was done for the sample of endotracheal tube aspirates. n= 1, 4, 2, 3, 1, 0; total = 11. Here, 'n' = participants with data available for the specific category. '9999' = Not Available; data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	5.36	5.58	6.09
standard deviation	± 9999	± 3.554	± 0.840
SARS-CoV-2 RNA Viral Load: Rectal/Fecal Swabs			
The assessment was done for the sample of rectal/fecal swabs. n= 8, 7, 8, 11, 3, 5; total = 42. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	3.30	2.63	2.72
standard deviation	± 1.593	± 0.757	± 1.034

Reporting group values	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Number of subjects	12	3	5
Age categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Newborns (0-27 days)	0	3	0
Infants and toddlers (28 days-23 months)	12	0	0
Children (2-11 years)	0	0	5
Adolescents (12-17 years)	0	0	0
Preterm newborn - gestational age < 37 wk			
Gender categorical			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Female	7	1	3
Male	5	2	2
Race			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
White	8	3	3
Black or African American	2	0	1
Other or More Than One Race	2	0	1
Ethnicity			
Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			

Not Hispanic or Latino	9	3	2
Hispanic or Latino	3	0	3
Unknown or Not Reported	0	0	0
Number of Participants With Clinical Status (7-Point Ordinal Scale) Score			
7-point scale: 1.Death;2.Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation(ECMO);3.Hospitalized, on noninvasive ventilation or high-flow oxygen devices;4.Hospitalized,requiring low-flow supplemental oxygen;5.Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care(COVID-19 related/otherwise);6.Hospitalized, not requiring supplemental oxygen-no longer requiring ongoing medical care(other than per-protocol RDV administration);7.Not hospitalized. Cohorts 6,7 are not reported due to participants' confidentiality			
Units: Subjects			
Score 1	0	0	0
Score 2	5	2	0
Score 3	3	1	2
Score 4	3	0	2
Score 5	0	0	1
Score 6	1	0	0
Score 7	0	0	0
Oxygen Support Status			
Oxygen support status was derived from the 7-point ordinal scale, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Participants with Baseline oxygen status for scores: 2 'invasive mechanical ventilation'; 3 'High Flow Oxygen'; 4 'Low Flow Oxygen', and 5 or 6 'Room Air' are reported. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
High-flow oxygen	3	1	2
Low-flow oxygen	3	0	2
Room air	1	0	1
Invasive mechanical ventilation	5	2	0
Pediatric Early Warning Score (PEWS) Scale Score: Behavior			
Behavior:0=playing; appropriate; 1=sleeping; 2=irritable; 3=lethargic; confused; reduced response to pain. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Behavior: Score 0	2	0	2
Behavior: Score 1	3	1	1
Behavior: Score 2	3	0	1
Behavior: Score 3	4	2	1
PEWS: Cardiovascular Score			
Cardiovascular:0=normal; pink; capillary refill (cr) 1-2 seconds(secs);1=Tachycardia< 20 above normal for age;2=Tachycardia 20-29 above normal for age; gray; cr=4 secs;3=Tachycardia >=30 above/bradycardia >=10 below normal for age; Gray; cr>=5 secs. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: Subjects			
Cardiovascular: Score 0	8	1	2
Cardiovascular: Score 1	1	2	3
Cardiovascular: Score 2	1	0	0
Cardiovascular: Score 3	2	0	0
PEWS: Respiratory Score			
Respiratory:0=Normal;1=Respiratory rate(rr)>10 above normal using accessory muscles; 30+%fraction of inspired oxygen(FiO2)/3+L/min; 2= rr>20 above normal and retractions;40%FiO2 or 6+L/min; 3 =rr>=5 below normal with retractions and grunting; 50%FiO2/8+L/min. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			

Units: Subjects			
Respiratory: Score 0	4	0	2
Respiratory: Score 1	0	1	0
Respiratory: Score 2	3	0	1
Respiratory: Score 3	5	2	2
SARS-CoV-2 RNA Viral Load: Nasal/Oropharyngeal (OP) Swabs			
The assessment was done for the sample of nasal/OP swab. n= 5, 5, 4, 3, 1, 1; total = 19. Here, 'n' = participants with data available for the specific category. '9999' = Not available, data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	5.41	5.02	6.20
standard deviation	± 2.165	± 9999	± 9999
SARS-CoV-2 RNA Viral Load: Nasopharyngeal (NP)/ OP Swabs			
The assessment was done for the sample of NP/OP swab. n= 5, 4, 5, 7, 2, 4; total = 27. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	5.55	5.99	6.12
standard deviation	± 1.854	± 0.183	± 1.628
SARS-CoV-2 RNA Viral Load: Endotracheal Tube Aspirates			
The assessment was done for the sample of endotracheal tube aspirates. n= 1, 4, 2, 3, 1, 0; total = 11. Here, 'n' = participants with data available for the specific category. '9999' = Not Available; data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	6.68	4.63	99999
standard deviation	± 1.540	± 9999	± 99999
SARS-CoV-2 RNA Viral Load: Rectal/Fecal Swabs			
The assessment was done for the sample of rectal/fecal swabs. n= 8, 7, 8, 11, 3, 5; total = 42. Here, 'n' = participants with data available for the specific category. Data for Cohorts 6 and 7 are not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups for arm-wise data.			
Units: log10 copies per mL			
arithmetic mean	3.84	4.27	2.75
standard deviation	± 1.341	± 1.107	± 1.274

End points

End points reporting groups

Reporting group title	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg
Reporting group description:	
Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to <40kg
Reporting group description:	
Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to <20kg
Reporting group description:	
Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Reporting group description:	
Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg
Reporting group description:	
Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 6:Age≥0-<14 Days, Gest. Age>37 Weeks;Weight≥2.5kg
Reporting group description:	
Participants received RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV,Cohort 7:Age≥0-<56 Days, Gest. Age≤37 Weeks;Weight≥1.5kg
Reporting group description:	
Participants received RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV infusion daily up to 10 days.	
Reporting group title	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Reporting group description:	
Participants received RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to<40kg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.	
Subject analysis set title	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kgto<20kg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion daily up to 10 days.

Subject analysis set title	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days

Subject analysis set title	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight≥2.5kg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.

Subject analysis set title	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

End point title	Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)[1][2]

End point description:

TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Analysis Population Description: Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.

End point type	Primary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The statistical analyses were not available for this endpoint. Only descriptive data provided were analysed.
[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: percentage of participants				
number (not applicable)	91.7	58.3	75.0	58.3

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: percentage of participants				
number (not applicable)	66.7	80.0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities

End point title	Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities[3][4]

End point description:

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days. The laboratory abnormalities were graded using division of allergy and infectious diseases (DAIDS) scale. DAIDS scale is used to grade the severity of adult and pediatric unwanted medical events. Grade 1: mild event, Grade 2: moderate event, Grade: serious event, Grade 4: potentially life-threatening event.

Analysis Population Description: Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug. Here, 'n'= number of participants with data available for analyses.

End point type	Primary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The statistical analyses were not available for this endpoint. Only descriptive data provided were analysed.
[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: percentage of participants				
number (not applicable)				
Any grade	100	83.3	91.7	90.9
Grade 3 or 4	75.0	16.7	41.7	36.4

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: percentage of participants				
number (not applicable)				
Any grade	100	80.0		
Grade 3 or 4	100	60.0		

Statistical analyses

No statistical analyses for this end point

Primary: Pharmacokinetic (PK) Parameter: Cmax of Remdesivir and its Metabolites GS-704277 and GS-441524 at Steady State

End point title	Pharmacokinetic (PK) Parameter: Cmax of Remdesivir and its Metabolites GS-704277 and GS-441524 at Steady State[5][6]

End point description:

Cmax is defined as maximum plasma concentration of drug. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Days 2 and 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

Analysis Population Description: The RDV PK Analysis Set included all enrolled participants who received at least 1 dose of RDV and for whom PK concentrations of RDV were available.
The Metabolites PK Analysis Set included all enrolled participants who received at least 1 dose of RDV and for whom PK concentrations of metabolites were available.

End point type	Primary

End point timeframe:

Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The statistical analyses were not available for this endpoint. Only descriptive data provided were analysed.
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	11	10
Units: ng/mL				

arithmetic mean (standard deviation)				
Remdesivir	4108.7 (± 1365.15)	6003.5 (± 1879.86)	5980.1 (± 2284.08)	5192.9 (± 2066.65)
GS-704277	360.6 (± 208.11)	469.0 (± 239.72)	484.8 (± 244.07)	407.8 (± 132.45)
GS-441524_	276.4 (± 327.14)	210.5 (± 121.02)	186.5 (± 103.09)	209.8 (± 49.73)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: ng/mL				
arithmetic mean (standard deviation)				
Remdesivir	4829.0 (± 956.16)	4235.7 (± 1790.53)		
GS-704277	466.0 (± 110.87)	297.9 (± 160.18)		
GS-441524_	371.8 (± 151.10)	230.4 (± 255.03)		

Statistical analyses

No statistical analyses for this end point

Primary: PK Parameter: AUCtau of Remdesivir and its Metabolites GS-704277 and GS-441524 at Steady State

End point title	PK Parameter: AUCtau of Remdesivir and its Metabolites GS-704277 and GS-441524 at Steady State[7][8]

End point description:

AUCtau is defined as area under the concentration versus time curve over the dosing interval. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Days 2 and 3, with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

Analysis Population Description: The RDV PK Analysis Set included all enrolled participants who received at least 1 dose of RDV and for whom PK concentration data of RDV were available.
The Metabolites PK Analysis Set included all enrolled participants who received at least 1 dose of RDV and for whom PK concentration data of metabolites were available.

End point type	Primary

End point timeframe:

Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were not available for this endpoint. Only descriptive data provided were analysed.
[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the

baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	11	10
Units: h*ng/mL				
arithmetic mean (standard deviation)				
Remdesivir	2630.1 (± 923.85)	3937.9 (± 1981.40)	6752.1 (± 10911.98)	3625.7 (± 3361.19)
GS-704277	1222.9 (± 1348.12)	860.3 (± 512.58)	876.0 (± 720.39)	776.0 (± 485.18)
GS-441524_	5486.2 (± 7599.27)	3016.1 (± 2425.78)	2751.8 (± 1868.93)	2969.1 (± 940.73)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: h*ng/mL				
arithmetic mean (standard deviation)				
Remdesivir	2650.3 (± 587.77)	2519.6 (± 1235.49)		
GS-704277	1049.0 (± 253.73)	671.4 (± 553.30)		
GS-441524_	6899.3 (± 3910.28)	4336.8 (± 5692.30)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Clinical Improvement on a 7-point Ordinal Scale

End point title	Percentage of Participants With Clinical Improvement on a 7-point Ordinal Scale[9]

End point description:

The 7-point ordinal scales were: 1 = death; 2 = hospitalized, on invasive mechanical ventilation or ECMO; 3 = hospitalized, on non-invasive ventilation or high flow oxygen devices; 4 = hospitalized, requiring low flow supplemental oxygen; 5 = hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID 19 related or otherwise); 6 = hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol RDV administration); 7 = not hospitalized. Participants with ≥ 1-point; ≥ 2-point improvement on scale and recovery are reported. Recovery is defined as an improvement from a baseline score of 2 through 5 to a score of 6 or 7 or an improvement from a baseline score of 6 to a score of 7. Participants from FAS population with data

available for analysis. Here 'n' are participants analysed.

End point type	Secondary

End point timeframe:

Day 10

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12[10]
Units: percentage of participants				
number (confidence interval 95%)				
≥ 1-point Improvement from Baseline	50.0 (21.1 to 78.9)	91.7 (61.5 to 99.8)	100 (73.5 to 100)	58.3 (27.7 to 84.8)
≥ 2-point Improvement from Baseline	41.7 (15.2 to 72.3)	91.7 (61.5 to 99.8)	100 (73.5 to 100)	54.5 (23.4 to 83.3)
Recovery	25.0 (5.5 to 57.2)	75.0 (42.8 to 94.5)	91.7 (61.5 to 99.8)	41.7 (15.2 to 72.3)

Notes:

[10] - n=12,11,12

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: percentage of participants				
number (confidence interval 95%)				
≥ 1-point Improvement from Baseline	33.3 (0.8 to 90.6)	80.0 (28.4 to 99.5)		
≥ 2-point Improvement from Baseline	33.3 (0.8 to 90.6)	80.0 (28.4 to 99.5)		
Recovery	33.3 (0.8 to 90.6)	80.0 (28.4 to 99.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time (Days) to Discharge From Hospital

End point title	Time (Days) to Discharge From Hospital[11]

End point description:

Time to discharge is defined as duration from first dose date to getting discharged from the hospital.

Analysis Population Description: The participants in the Full Analysis Set who were discharged alive on or prior to Day 30 were analysed.

Description for '999' = Median and upper bound of range (Q3) could not be calculated because less than 50% and 75% of participants, respectively, experienced the event. Hence the days were reported as '999'.

End point type	Secondary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: days				
median (inter-quartile range (Q1-Q3))	12 (8 to 24)	7 (5 to 9)	5 (4 to 9)	7 (4 to 19)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: days				
median (inter-quartile range (Q1-Q3))	999 (9 to 999)	10 (4 to 18)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Change From Baseline in Oxygenation Use

End point title	Number of Participants With Change From Baseline in Oxygenation Use[12]

End point description:

Oxygen support status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Participants with shift from Baseline in scores are reported.

Analysis Population Description: Participants in Full Analysis Set with Oxygenation use status as 'High Flow Oxygen', 'Low Flow Oxygen' and 'Room Air' at Baseline were analysed.

End point type	Secondary

End point timeframe:

Day 10

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11[13]	9[14]	9[15]	7[16]
Units: percentage of participants				
number (not applicable)				
High flow oxygen (HFO) (Baseline); Death (Day 10)	0	0	0	0
HFO (Baseline); IMV (Day 10)	2	0	0	0
HFO (Baseline); HFO (Day 10)	1	0	0	0
HFO (Baseline); Low Flow oxygen (LFO) (Day 10)	0	0	0	0
HFO (Baseline); Room Air (Day 10)	2	0	0	0
HFO (Baseline); Discharge (Day 10)	1	4	3	2
HFO (Baseline); Missing (Day 10)	0	0	0	1
LFO (Baseline); Death (Day 10)	0	0	0	0
LFO (Baseline); IMV (Day 10)	0	0	0	0
LFO (Baseline); HFO (Day 10)	0	0	0	0
LFO (Baseline); LFO (Day 10)	0	0	0	1
LFO (Baseline); Room Air (Day 10)	1	0	0	0
LFO (Baseline); Discharge (Day 10)	1	3	0	2
LFO (Baseline); Missing (Day 10)	0	0	0	0
Room Air (Baseline); Death (Day 10)	0	0	0	0
Room Air (Baseline); IMV (Day 10)	0	0	0	0
Room Air (Baseline); HFO (Day 10)	0	0	0	0
Room Air (Baseline); LFO (Day 10)	0	0	0	0
Room Air (Baseline); Room Air (Day 10)	2	0	0	0
Room Air (Baseline); Discharge (Day 10)	1	2	6	1
Room Air (Baseline); Missing (Day 10)	0	0	0	0

Notes:

[13] - High flow oxygen (n=6),Low flow oxygen (n=2),Room air (n=3)

[14] - High flow oxygen(n=4), Low flow oxygen(n=3), Room air(n=2)

[15] - High flow oxygen(n=3), Low flow oxygen(n=0), Room air(n=6)

[16] - High flow oxygen(n=3), Low flow oxygen(n=3), Room air(n=1)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1[17]	5[18]		

Units: percentage of participants				
number (not applicable)				
High flow oxygen (HFO) (Baseline); Death (Day 10)	0	0		
HFO (Baseline); IMV (Day 10)	0	1		
HFO (Baseline); HFO (Day 10)	0	0		
HFO (Baseline); Low Flow oxygen (LFO) (Day 10)	0	0		
HFO (Baseline); Room Air (Day 10)	0	0		
HFO (Baseline); Discharge (Day 10)	1	1		
HFO (Baseline); Missing (Day 10)	0	0		
LFO (Baseline); Death (Day 10)	0	0		
LFO (Baseline); IMV (Day 10)	0	0		
LFO (Baseline); HFO (Day 10)	0	0		
LFO (Baseline); LFO (Day 10)	0	0		
LFO (Baseline); Room Air (Day 10)	0	1		
LFO (Baseline); Discharge (Day 10)	0	1		
LFO (Baseline); Missing (Day 10)	0	0		
Room Air (Baseline); Death (Day 10)	0	0		
Room Air (Baseline); IMV (Day 10)	0	0		
Room Air (Baseline); HFO (Day 10)	0	0		
Room Air (Baseline); LFO (Day 10)	0	0		
Room Air (Baseline); Room Air (Day 10)	0	0		
Room Air (Baseline); Discharge (Day 10)	0	1		
Room Air (Baseline); Missing (Day 10)	0	0		

Notes:

[17] - High flow oxygen(n=1), Low flow oxygen(n=0), Room air(n=0)

[18] - High flow oxygen(n=2), Low flow oxygen(n=2), Room air(n=1)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)

End point title	Number of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)[19]

End point description:

Mechanical ventilation status was derived from the 7-point ordinal scale, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Participants with shift from Baseline in scores are reported. Only categories with data are reported.

Analysis Population Description: Participants in Full Analysis Set with Oxygenation use status as 'Mechanical Ventilation or ECMO' at Baseline were analysed.

Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in this group.

End point type	Secondary

End point timeframe:

Day 10

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as

there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	3	3	5
Units: participants				
Death	0	0	0	0
Invasive Mechanical ventilation	1	1	0	2
High Flow Oxygen	0	0	0	0
Low Flow Oxygen	0	1	0	0
Room Air	0	0	1	2
Discharge	0	0	2	0
Missing	0	1	0	1

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	0[20]		
Units: participants				
Death	0			
Invasive Mechanical ventilation	2			
High Flow Oxygen	0			
Low Flow Oxygen	0			
Room Air	0			
Discharge	0			
Missing	0			

Notes:

[20] - No participant had the baseline score of 2 in this cohort.

Statistical analyses

No statistical analyses for this end point

Secondary: Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result

End point title	Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result[21]

End point description:

Confirmed negative PCR is defined by as 2 consecutive negative PCR results or negative result at the last available sample for participants who completed or discontinued from the study. The assessments were done for the samples: nasal/oropharyngeal (OP), nasopharyngeal (NP)/oropharyngeal (OP), endotracheal (ET) aspirates, and rectal/fecal swabs.

Analysis Population Description: The Full Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.

Description for '9999' = Median days to event could not be calculated because less than 50% of participants experienced the event. Hence the days were reported as '9999'.

End point type	Secondary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: days				
median (inter-quartile range (Q1-Q3))				
Nasal/OP Samples	9999 (5 to 9999)	5 (3 to 9999)	7 (5 to 9999)	9999 (4 to 9999)
NP/OP Samples	9999 (9999 to 9999)	9999 (7 to 9999)	9999 (5 to 9999)	9999 (10 to 9999)
ET Aspirates	9999 (9999 to 9999)	9999 (3 to 9999)	9999 (9999 to 9999)	9999 (3 to 9999)
Rectal/Faecal Samples	5 (3 to 10)	3 (3 to 5)	5 (3 to 9999)	7 (5 to 9999)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: days				
median (inter-quartile range (Q1-Q3))				
Nasal/OP Samples	10 (10 to 10)	9999 (9999 to 9999)		
NP/OP Samples	9999 (9999 to 9999)	9999 (9999 to 9999)		
ET Aspirates	9999 (9999 to 9999)	9999 (9999 to 9999)		
Rectal/Faecal Samples	3 (3 to 5)	4 (3 to 7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in SARS-CoV-2 Viral Load up to Day 10 or up to the First Confirmed Negative PCR Result

End point title	Change from Baseline in SARS-CoV-2 Viral Load up to Day 10 or up to the First Confirmed Negative PCR Result[22]

End point description:

Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first) were reported. The assessments were done for the samples: nasal/OP samples; NP/OP samples; ET aspirates; rectal or fecal swabs. Here, 'n'=participants with data available for the specific category.

Analysis Population Description: The Full Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug. Number analyzed are participants with data available for analysis for the specific category.

'9999'=SD could not be estimated for 1 participant. '99999'=No participants.

End point type	Secondary

End point timeframe:

Baseline, Day 10, and Day of Discharge (Day 10 or before)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12[23]	12[24]	12[25]	12[26]
Units: log10 copies per mL				
arithmetic mean (standard deviation)				
Nasal/OP Samples, Change at Day 10	-3.01 (± 9999)	99999 (± 99999)	0 (± 0)	99999 (± 99999)
Nasal/OP Samples, Change at Discharge	99999 (± 99999)	-4.65 (± 9999)	99999 (± 99999)	-1.56 (± 1.228)
NP/OP Samples, Change at Day 10	99999 (± 99999)	-2.17 (± 2.197)	99999 (± 99999)	-2.60 (± 1.283)
NP/OP Samples, Change at Discharge	-2.86 (± 9999)	-3.72 (± 9999)	-0.87 (± 1.391)	1.42 (± 9999)
ET aspirates, Change at Day 10	99999 (± 99999)	-5.94 (± 9999)	99999 (± 99999)	99999 (± 99999)
ET aspirates, Change at Discharge	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)
Rectal or Fecal Swabs, Change at Day 10	0.38 (± 9999)	-0.39 (± 9999)	99999 (± 99999)	-1.87 (± 9999)
Rectal or Fecal Swabs, Change at Discharge	99999 (± 99999)	1.12 (± 9999)	-0.09 (± 1.999)	-1.47 (± 0.479)

Notes:

[23] - n=1,0,0,1,0,0,1,0

[24] - n=0,1,2,1,1,0,1,1

[25] - n=1,0,0,3,0,0,0,2

[26] - n=0,2,3,1,0,0,1,3

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		

	Weeks;Weight ≥2.5kg			
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3[27]	5[28]		
Units: log10 copies per mL				
arithmetic mean (standard deviation)				
Nasal/OP Samples, Change at Day 10	-2.36 (± 9999)	-1.76 (± 9999)		
Nasal/OP Samples, Change at Discharge	99999 (± 99999)	99999 (± 99999)		
NP/OP Samples, Change at Day 10	-3.28 (± 0.183)	0.46 (± 9999)		
NP/OP Samples, Change at Discharge	99999 (± 99999)	-0.05 (± 1.184)		
ET aspirates, Change at Day 10	-1.92 (± 9999)	99999 (± 99999)		
ET aspirates, Change at Discharge	99999 (± 99999)	99999 (± 99999)		
Rectal or Fecal Swabs, Change at Day 10	99999 (± 99999)	1.38 (± 9999)		
Rectal or Fecal Swabs, Change at Discharge	99999 (± 99999)	0 (± 0)		

Notes:

[27] - n=1,0,2,0,1,0,0,0

[28] - n=1,0,1,3,0,0,1,2

Statistical analyses

No statistical analyses for this end point

Secondary: Bilirubin Concentrations in < 14-day-old Participants

End point title	Bilirubin Concentrations in < 14-day-old Participants[29]

End point description:

Analysis Population Description: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

No data displayed because Outcome Measure has zero total participants analysed.

End point type	Secondary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was applicable only for cohorts 6 and 7.

End point values	RDV,Cohort 6:Age≥0-<14 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV,Cohort 7:Age≥0-<56 Days, Gest. Age≤37 Weeks;Weight ≥1.5kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[30]	0[31]		
Units: mg/dL				
arithmetic mean (standard deviation)	()	()		

Notes:

[30] - Data were not reported due to participants' confidentiality reasons.

[31] - Data were not reported due to participants' confidentiality reasons.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale

End point title	Percentage of Participants Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale[32]

End point description:

The PEWS was measured by 3 components, where 1= behavior, 2= perfusion assessed by capillary refill and heart rate, and 3= respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranged between 0 to 9 point, with higher score representing the highest severity level. A negative change from baseline value indicated an improvement. Data are reported for participants with a PEWS behavior score ≥ 2 at baseline, and a ≥ 2-point improvement (indicated by a decrease) in PEWS behavior score by Day 10, participants with a PEWS behavior score ≥ 1 at baseline, with ≥ 1-point improvement in PEWS behavior score by Day 10 and participants who recovered in PEWS behavior, defined as a Baseline score of 1 through 3 improved to a score of 0.

The Full Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug. Here 'n' are participants with data available for analyses for the specific category.

End point type	Secondary

End point timeframe:

Day 10

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: percentage of participants				
number (confidence interval 95%)				
≥ 2-point Improvement from Baseline-Respiratory	33.3 (4.3 to 77.7)	83.3 (35.9 to 99.6)	75 (19.4 to 99.4)	42.9 (9.9 to 81.6)
≥ 1-point Improvement from Baseline-Respiratory	50.0 (15.7 to 84.3)	81.8 (48.2 to 97.7)	83.8 (35.9 to 99.6)	42.9 (9.9 to 81.6)
Recovery- Respiratory	37.5 (8.5 to 75.5)	81.8 (48.2 to 97.7)	83.3 (35.9 to 99.6)	42.9 (9.9 to 81.6)
≥ 2-point Improvement from Baseline-Behavior	0 (0 to 84.2)	33.3 (0.8 to 90.6)	100 (47.8 to 100)	66.7 (22.3 to 95.7)
≥ 1-point Improvement from Baseline-Behavior	40 (5.3 to 85.3)	66.7 (22.3 to 95.7)	100 (59 to 100)	66.7 (29.9 to 92.5)
Recovery- Behavior	40 (5.3 to 85.3)	66.7 (22.3 to 95.7)	100 (59 to 100)	55.6 (21.2 to 86.3)

≥ 2-point Improvement from Baseline-Cardiovascular	0 (0 to 84.2)	66.7 (9.4 to 99.2)	100 (15.8 to 100)	100 (15.8 to 100)
≥ 1-point Improvement from Baseline-Cardiovascular	33.3 (0.8 to 90.6)	80 (28.4 to 99.5)	100 (47.8 to 100)	66.7 (9.4 to 99.2)
Recovery- Cardiovascular	0 (0 to 70.8)	80 (28.4 to 99.5)	100 (47.8 to 100)	33.3 (0.8 to 90.6)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: percentage of participants				
number (confidence interval 95%)				
≥ 2-point Improvement from Baseline-Respiratory	0 (0 to 84.2)	66.7 (9.4 to 99.2)		
≥ 1-point Improvement from Baseline-Respiratory	33.3 (0.3 to 90.6)	66.7 (9.4 to 99.2)		
Recovery- Respiratory	33.3 (0.8 to 90.6)	66.7 (9.4 to 99.2)		
≥ 2-point Improvement from Baseline-Behavior	0 (0 to 84.2)	50 (1.3 to 98.7)		
≥ 1-point Improvement from Baseline-Behavior	66.7 (9.4 to 99.2)	33.3 (0.8 to 90.6)		
Recovery- Behavior	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)		
≥ 2-point Improvement from Baseline-Cardiovascular	0 (0 to 0)	0 (0 to 0)		
≥ 1-point Improvement from Baseline-Cardiovascular	50 (1.3 to 98.7)	66.7 (9.4 to 99.2)		
Recovery- Cardiovascular	50 (1.3 to 98.7)	66.7 (9.4 to 99.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)

End point title	Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)[33]

End point description:

Plasma concentrations were drawn as follows: (1) for cohorts 1-4 and 8 on Day 2 and Day 3, with Day 5 as optional; (2) for cohorts 5-7 on Day 2 or Day 3.

Analysis Population Description: The SBECD PK Analysis Set included all participants who were enrolled and received at least 1 dose of RDV and for whom PK concentrations of SBECD were available. Here, 'n' = participants with data available for the specific category.

Description for '9999' = Data were not available as the concentrations were below the level of quantification (BLQ). '99999' = No participants.

End point type	Secondary

End point timeframe:

Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12[34]	12[35]	11[36]	10[37]
Units: ug/mL				
arithmetic mean (standard deviation)				
Day 2, End of Infusion	217.7 (± 262.32)	173.0 (± 119.06)	187.8 (± 75.89)	138.3 (± 104.06)
Day 2, 4 Hours	110.1 (± 270.72)	24.3 (± 23.90)	14.2 (± 15.03)	36.2 (± 32.75)
Day 3, Pre-Infusion	78.5 (± 209.65)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
Day 3, 2 Hours	90.1 (± 221.54)	47.5 (± 52.62)	47.4 (± 38.99)	58.2 (± 25.89)
Day 5, Middle of Infusion	229.0 (± 221.14)	105.5 (± 72.05)	156.3 (± 23.12)	118.2 (± 121.22)
Day 5, 6 Hours	141.2 (± 261.96)	6.6 (± 3.15)	9999 (± 9999)	12.4 (± 9.89)

Notes:

[34] - (n=10,10,10, 11,6,3)

[35] - (n=12,11,10,12,5,4)

[36] - (n=10,10,10,9,3,2)

[37] - (n=9,9,8,7,5,4)

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3[38]	5[39]		
Units: ug/mL				
arithmetic mean (standard deviation)				
Day 2, End of Infusion	9999 (± 9999)	156.6 (± 57.21)		
Day 2, 4 Hours	9999 (± 9999)	16.2 (± 8.31)		
Day 3, Pre-Infusion	9999 (± 9999)	9999 (± 9999)		
Day 3, 2 Hours	61.0 (± 79.20)	48.0 (± 50.41)		
Day 5, Middle of Infusion	99999 (± 99999)	184.2 (± 131.82)		
Day 5, 6 Hours	99999 (± 99999)	9999 (± 9999)		

Notes:
[38] - (n=1,1,2,2,0,0)
[39] - (n=5,4,5,5,3,2)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)

End point title	Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)[40]

End point description:

Participants who received at least one concomitant non study COVID-19 medication from the first day of RDV treatment through the 30-day Follow-up visit or early withdrawal are reported.
Analysis Population Description: The Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug. Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point type	Secondary

End point timeframe:

From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Data for Cohorts 6 and 7 were not reported due to participants' confidentiality reasons as there was only 1 participant in each of these groups.

End point values	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥40 kg	RDV,Cohort 2:Age ≥28 Days to <18 Years;Weight ≥20 kg to	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to	RDV,Cohort 4:Age ≥28 Days to <18 Years;Weight ≥3kg to <12kg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	12	12	12
Units: percentage of participants				
number (not applicable)	100	100	83.3	83.3

End point values	RDV,Cohort 5:Age≥14-<28 Days, Gest. Age>37 Weeks;Weight ≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	5		
Units: percentage of participants				
number (not applicable)	66.7	100		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-Cause Mortality: First dose date up to approximately 8 weeks;
Adverse events: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

Adverse event reporting additional description:

All-cause mortality: All Enrolled Analysis Set will include all subjects who are enrolled into the study.
Adverse events: Safety Analysis Set included all enrolled participants who received at least one dose of study drug.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.0

Reporting groups

Reporting group title	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥ 40 kg

Reporting group description:

Patients who received RDV Cohort 1: Age 12 to <18 Years and Weight ≥40 kg

Reporting group title	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to <40kg

Reporting group description:

Patients who received RDV Cohort 2: Age 28 Days to <18 Years and Weight 20 to <40 kg

Reporting group title	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to<20kg

Reporting group description:

Patients who received RDV Cohort 3: Age 28 Days to <18 Years and Weight 12 to <20 kg

Reporting group title	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg

Reporting group description:

Patients who received RDV Cohort 4: Age 28 Days to <18 Years and Weight 3 to <12 kg

Reporting group title	RDV,Cohort 5:Age≥14-<28 Days, Birth Age>37 Weeks;Weight≥2.5kg

Reporting group description:

Patients who received RDV Cohort 5: Age 14 to <28 Days, Gest. Age > 37 Wks. and Weight ≥ 2.5 kg

Reporting group title	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg

Reporting group description:

Patients who received RDV Cohort 8: Age <12 Years and Weight ≥40 kg

Serious adverse events	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥ 40 kg	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to <40kg	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to<20kg
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 12 (41.67%)	2 / 12 (16.67%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Haemodynamic instability			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Seizure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction ~ syndrome			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrointestinal necrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumoperitoneum			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory distress			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Negative pressure pulmonary ~ oedema			

subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acidosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg	RDV,Cohort 5:Age≥14-<28 Days, Birth Age>37 Weeks;Weight≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 12 (25.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Haemodynamic instability			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Thrombosis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple organ dysfunction ~ syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal disorders			
Gastrointestinal necrosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumoperitoneum			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Respiratory distress			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Negative pressure pulmonary ~ oedema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypocalcaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hyperkalaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acidosis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	RDV, Cohort 1: Age 12 to <18 Years and Weight ≥ 40 kg	RDV,Cohort 2:Age ≥ 28 Days to< 18 Years;Weight ≥20 kg to <40kg	RDV,Cohort 3:Age≥28 Days to <18Years;Weight ≥12 kg to<20kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 12 (91.67%)	7 / 12 (58.33%)	9 / 12 (75.00%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	2 / 12 (16.67%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	2	1	0
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Physical deconditioning			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Inflammation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Chest pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Catheter site pain			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 12 (16.67%)	1 / 12 (8.33%)
occurrences (all)	0	2	1
Infusion site extravasation			
subjects affected / exposed	0 / 12 (0.00%)	2 / 12 (16.67%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Hypogammaglobulinaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Pneumomediastinum			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Bronchospasm			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Dyspnoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lung opacity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Respiratory acidosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory distress			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory failure			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Agitation			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	2 / 12 (16.67%)
occurrences (all)	0	1	2
Delirium			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Product issues			
Device leakage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Device occlusion			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 12 (16.67%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Bacterial test positive			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood calcium decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Blood glucose decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Blood phosphorus decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	3	0	0
Blood potassium decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Blood sodium increased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Breath sounds abnormal			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vitamin C decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram ST segment elevation			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Haemoglobin decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Oxygen saturation abnormal			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Calcium ionised decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Congenital, familial and genetic disorders			
Ventricular septal defect			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Coronary artery dilatation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Extrasystoles			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Left ventricular dysfunction			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Bradycardia			
subjects affected / exposed	0 / 12 (0.00%)	2 / 12 (16.67%)	0 / 12 (0.00%)
occurrences (all)	0	2	0
Cardiac arrest			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiomegaly			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Ventricular tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Myocarditis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			

subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	1 / 12 (8.33%)
occurrences (all)	0	1	1
Nausea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	3 / 12 (25.00%)	1 / 12 (8.33%)	2 / 12 (16.67%)
occurrences (all)	3	1	2
Abdominal pain upper			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Duodenal ulcer			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anal pruritus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Small intestinal obstruction			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Alopecia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	4 / 12 (33.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	4	0	0
Polyuria			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Chest wall haematoma			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Systemic lupus erythematosus			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Myositis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Pseudomonal bacteraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pneumonia cytomegaloviral			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pneumonia bacterial			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			

subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Bacterial disease carrier			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Fungal cystitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Hypoalbuminaemia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Hypomagnesaemia			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 12 (8.33%)	1 / 12 (8.33%)
occurrences (all)	2	1	1
Vitamin K deficiency			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Hypoglycaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Abnormal loss of weight			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 12 (0.00%)	1 / 12 (8.33%)	1 / 12 (8.33%)
occurrences (all)	0	1	1
Hypokalaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 12 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	RDV,Cohort 4:Age≥28 Days to< 18 Years;Weight≥3kg to <12kg	RDV,Cohort 5:Age≥14-<28 Days, Birth Age>37 Weeks;Weight≥2.5kg	RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 12 (58.33%)	2 / 3 (66.67%)	4 / 5 (80.00%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)
occurrences (all)	0	2	2
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Physical deconditioning			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Inflammation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infusion site extravasation			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypogammaglobulinaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Pneumomediastinum			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Bronchospasm			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Dyspnoea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Lung opacity			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Respiratory acidosis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Respiratory distress			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Agitation			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Product issues			
Device leakage			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Device occlusion			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Bacterial test positive			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood glucose decreased			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood sodium increased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Vitamin C decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram ST segment elevation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation abnormal			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Calcium ionised decreased			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			

Ventricular septal defect			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Coronary artery dilatation			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Extrasystoles			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Left ventricular dysfunction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Cardiac arrest			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Cardiomegaly			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ventricular tachycardia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myocarditis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Presyncope			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 12 (8.33%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	1	2	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Constipation			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	3 / 5 (60.00%)
occurrences (all)	1	0	3
Abdominal pain upper			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dysphagia			

subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Duodenal ulcer			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Anal pruritus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Pancreatitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Ileus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Rash maculo-papular			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Alopecia			

subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Skin disorder			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Polyuria			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Chest wall haematoma			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myositis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Muscular weakness			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Pseudomonal bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pneumonia bacterial			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Bacterial disease carrier			
subjects affected / exposed	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Fungal cystitis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hypoalbuminaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	1	0	2
Hyperglycaemia			

subjects affected / exposed	2 / 12 (16.67%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Vitamin K deficiency			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Tumour lysis syndrome			
subjects affected / exposed	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hypophosphataemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abnormal loss of weight			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 June 2020	• Added Exclusion criteria #8 for positive pregnancy at Screening. • Specified that the respiratory rate was not to be collected for subjects that were not on a ventilator. • Clarified that blood/urine screening samples were not needed to be repeated if done in the preceding 48 hours. • Updated the SARS-CoV-2 PCR testing and viral sequencing to include nasal and oropharyngeal samples (combined). • Added "and HCl and NaOH for pH adjustment." To RDV formulation for clarity. • Updated the eGFR units to (mL/min/1.73 m2) to add /1.73 m2 throughout document. • Updated the collection of Apgar score at 10 min to last recorded score throughout document. • Clarified the Prohibited Concomitant Medications to include Investigational agents for COVID-19 with direct antiviral effect and added rifabutin, carbamazepine, phenytoin. • Added Contraceptive requirement for participating subjects at Screening and during the study as outlined in the new Appendix. • Added the collection of 1 to 2 mL optional blood collection to Day 1 OR Day 4 for future analysis and updated Appendix. • Added instructions to use smallest possible blood vials for sample collection for subjects <15kg.
22 September 2020	• Increased the number of centers planned to 35. • Clarified the number of participants planned for the study as at least 52. • Added exploratory Cohort 8 for participants < 12 years ≥ 40kg and updated language throughout the document to include Cohort 8. • Clarified the PK collection windows. • Updated the Exploratory Objectives of the Study to include analysis for participants with BMI for age ≥ 95th percentile. • Clarified language for exclusion criteria #8 per FDA comment. • Added exclusion criteria #9 for participants on renal replacement therapies. • Clarified the screening window for laboratory assessments per FDA comment. • Clarified the k value in the Schwartz formula. • Updated renal replacement therapies as a criterion for discontinuation. • Updated Study Rationale to add latest findings from healthy volunteer studies as well as results from Simple and NAID studies. • Updated the Rationale for Dose Selection to remove age requirement. • Clarified the Risk/Benefit Assessment for participants ≥ 2 years and included pandemic risk management language. • Added Toxicity Management. • Updated the Samples for Optional Future Research language. • Included a new Appendix 6 for pandemic risk management. • Replaced "viral sequencing" with "viral resistance testing" throughout the document. • Updated SARS-CoV-2 PCR to SARS-CoV-2 RT-qPCR throughout the document. • Updated PVE to GLPS throughout document. • Made additional updates for clarity throughout the document. • Made additional formatting and administrative updates and minor grammatical corrections throughout the document; these are not explicitly outlined in the changes below. New text is indicated by Bold and Strikethrough.

16 February 2021	• Updated the List of In-Text Tables for consistency. • Updated Study Rationale to add safety information as presented in the current USPI labeling. • Added Grade 3/ 4 laboratory abnormalities that occurred in Studies NIAID ACTT-1, GS-US-540-5773 and GS-US-540-5774. • Revised the Risk/Benefit Assessment for treatment-emergent elevations in ALT and AST which were observed in healthy volunteers and study participants with COVID-19. • Updated the IMP Return or Disposal to add remote monitoring visits. • Updated the routine coagulation test for Cohorts 5, 6 and 7. • Revised the blood volume tables for Cohorts 5, 6 and 7. • Made additional updates for clarity throughout the document. • Made additional formatting and administrative updates and minor grammatical corrections throughout the document; these are not explicitly outlined in the changes below. New text is indicated by Bold and Strikethrough.
06 January 2022	• Incorporate the dose for Cohorts 6 (0 days to < 14 days of age, gestational age > 37 weeks and birth weight ≥ 2.5 kg) and 7 (0 days to < 56 days of age, gestational age ≤ 37 weeks and birth weight ≥ 1.5 kg). • The introduction was updated to incorporate a rationale for the dose selection for Cohorts 6 and 7. • The introduction was updated with current COVID-19 epidemiology data, as well as safety and efficacy data from a clinical study evaluating RDV in non-hospitalized participants with COVID-19 as well as interim results from the current study in pediatric participants with COVID-19. • Additional changes to the protocol include the following: • The following style update was made throughout the document: the term "subjects" was replaced with "participants". • Administrative, editorial, and formatting updates, changes, corrections, and clarifications were made throughout, where appropriate, including section numbering and references. • Changes in the body of the protocol were also updated in the synopsis and study procedures table(s), as appropriate.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported